All In Biotech

Drug Trial Radar · NCT07885956

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A SECOND DOSE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE GIVEN 5 YEARS AFTER THE INITIAL DOSE IN OLDER ADULTS

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Feb 7, 2029

Study completion Feb 7, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is testing the safety and tolerability of a second dose of Respiratory Syncytial Virus Vaccine (RSVpreF) given approximately 5 years after the initial dose.

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

  • RSVpreF (Regimen A)Biological

    Regimen A

  • RSVpreF (Regimen B)Biological

    Regimen B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting local reactionsTime frame: For up to 7 days after vaccination
  2. Percentage of participants reporting systemic eventsTime frame: For up to 7 days after vaccination
  3. Percentage of participants reporting adverse eventsTime frame: Through 1 month after vaccination
  4. Percentage of participants reporting newly diagnosed chronic medical conditionsTime frame: Through 18 months after vaccination
  5. Percentage of participants reporting serious adverse eventsTime frame: Through 18 months after vaccination

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Fiel Family and Sports Medicine/Avacare Clinical Research Network

    Tempe, Arizona

  • West Coast Research

    Dublin, California

  • Universal Axon Clinical Research

    Doral, Florida

  • Rovia - Palmetto Bay

    Miami, Florida

  • DBC Research USA

    Pembroke Pines, Florida

  • Javara Inc

    Albany, Georgia

  • Solaris Clinical Research

    Meridian, Idaho

  • Summit Headlands LLC

    Portland, Oregon

  • Accellacare US Inc., d/b/a Accellacare of Knoxville

    Knoxville, Tennessee

  • DM Clinical Research-Tomball

    Tomball, Texas

  • J. Lewis Research Inc. / Foothill Family Clinic Draper

    Draper, Utah

  • J. Lewis Research, Inc/Jordan River Family Medicine

    South Jordan, Utah

  • Sound Health Care Center

    Port Orchard, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.